Pharma company Zydus Cadila Healthcare said it has received US Food and Drug Administrator’s (USFDA) approval for a drug, used in the treatment of rheumatoid arthritis.
The company has received an approval from the USFDA for the new Disease Modifying Anti-Rheumatic Drug (DMARD) Hydroxychloroquine Sulfate tablets in the strength of 200 mg, Cadila said in a communique to the Bombay Stock Exchange.
DMARD is a medication patients with rheumatoid arthritis take to decrease pain and inflammation, prevent joint damage and preserve the structure of the joints. The drugs of this category provide relief over a period of time ranging from a few weeks to a few months.
The company would market the drug through its US-based subsidiary Zydus Pharmaceuticals (USA) Inc, Cadila Healthcare said.
Shares of the company were last trading 1.40 per cent down at Rs 299.05 on BSE.